help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Malik, S. W.
Right arrow Articles by Specks, U.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Malik, S. W.
Right arrow Articles by Specks, U.

Am. J. Respir. Crit. Care Med., Vol 154, No. 6, Dec 1996, 1851-1856.

Lung toxicity associated with cyclophosphamide use. Two distinct patterns

SW Malik, JL Myers, RA DeRemee and U Specks
Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN 55905, USA.

Cyclophosphamide-induced lung toxicity may be difficult to recognize because of the presence of confounding variables such as concomitant use of other cytotoxic drugs, opportunistic infections, diffuse pulmonary malignancy, radiation pneumonitis, and oxygen toxicity. The purpose of this retrospective analysis was to identify the clinical spectrum of pulmonary toxicity of cyclophosphamide. In our review of case records, we sought to identify patients in whom cyclophosphamide was the only identifiable etiologic factor for lung toxicity. In a 20- yr period six patients were identified with cyclophosphamide-induced lung disease, including five men and one woman ranging in age from 42 to 78 yr. Clinical features of toxicity include dyspnea, fever, cough, new parenchymal infiltrates, gas exchange abnormalities on pulmonary function tests, and pleural thickening on chest roentgenogram. Two patterns of cyclophosphamide-induced lung toxicity were identified. A single patient presented with early-onset pneumonitis and responded to discontinuation of the drug. Five patients with late-onset pneumonitis developed progressive pulmonary fibrosis associated with bilateral pleural thickening. Patients with late-onset pneumonitis showed no response to cessation of cyclophosphamide and institution of corticosteroid therapy. Three of these patients died of respiratory failure. Careful review of the individual cases reported in the literature as cyclophosphamide lung toxicity revealed only 12 cases in whom none of the additional confounding factors could be identified. These could easily be divided in the same two categories. Early-onset pneumonitis is reversible and may respond to corticosteroid therapy. Late-onset pneumonitis, frequently associated with pleural thickening, is clinically distinct from idiopathic pulmonary fibrosis but has a chronically progressive course. It appears unresponsive to corticosteroid therapy.


This article has been cited by other articles:


Home page
 ChestHome page
J. J. Swigris, A. Fischer, J. Gilles, R. T. Meehan, and K. K. Brown
Pulmonary and Thrombotic Manifestations of Systemic Lupus Erythematosus
Chest, January 1, 2008; 133(1): 271 - 280.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
N. Walter, H. R. Collard, and T. E. King Jr.
Current perspectives on the treatment of idiopathic pulmonary fibrosis.
Proceedings of the ATS, January 1, 2006; 3(4): 330 - 338.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
L. Joos and M. Tamm
Breakdown of Pulmonary Host Defense in the Immunocompromised Host: Cancer Chemotherapy
Proceedings of the ATS, December 1, 2005; 2(5): 445 - 448.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
S. K. Frankel, C. D. Cool, D. A. Lynch, and K. K. Brown
Idiopathic Pleuroparenchymal Fibroelastosis: Description of a Novel Clinicopathologic Entity
Chest, December 1, 2004; 126(6): 2007 - 2013.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
D. L. Helman Jr, J. C. Byrd, N. C. Ales, and A. F. Shorr
Fludarabine-Related Pulmonary Toxicity* : A Distinct Clinical Entity in Chronic Lymphoproliferative Syndromes
Chest, September 1, 2002; 122(3): 785 - 790.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
C. FUHRMAN, A. PARROT, M. WISLEZ, H. PRIGENT, V. BOUSSAUD, J.-F. BERNAUDIN, C. MAYAUD, and J. CADRANEL
Spectrum of CD4 to CD8 T-Cell Ratios in Lymphocytic Alveolitis Associated with Methotrexate-induced Pneumonitis
Am. J. Respir. Crit. Care Med., October 1, 2001; 164(7): 1186 - 1191.
[Abstract] [Full Text] [PDF]

Home page
 RadioGraphicsHome page
S. E. Rossi, J. J. Erasmus, H. P. McAdams, T. A. Sporn, and P. C. Goodman
Pulmonary Drug Toxicity: Radiologic and Pathologic Manifestations
RadioGraphics, September 1, 2000; 20(5): 1245 - 1259.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
P. Fulgoni, M. C. Zoia, A. Corsico, M. Beccaria, G. Georgiani, G. Bossi, and I. Cerveri
Lung Function in Survivors of Childhood Acute Lymphoblastic Leukemia
Chest, November 1, 1999; 116(5): 1163 - 1167.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
S. Y. Morelock and S. A. Sahn
Drugs and the Pleura
Chest, July 1, 1999; 116(1): 212 - 221.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
W. W. DOUGLAS, J. H. RYU, S. J. SWENSEN, K. P. OFFORD, D. R. SCHROEDER, G. M. CARON, R. A. DEREMEE, and Members of the Lung Study Group
Colchicine versus Prednisone in the Treatment of Idiopathic Pulmonary Fibrosis . A Randomized Prospective Study
Am. J. Respir. Crit. Care Med., July 1, 1998; 158(1): 220 - 225.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 1996 American Thoracic Society